Nuclear medicine vendor ADAC Laboratories enjoyed a banner firstquarter of fiscal 1997 (end-December). The Milpitas, CA, firmlast week reported quarterly financial results that indicateddouble-digit increases in both net income and revenues.For the
Nuclear medicine vendor ADAC Laboratories enjoyed a banner firstquarter of fiscal 1997 (end-December). The Milpitas, CA, firmlast week reported quarterly financial results that indicateddouble-digit increases in both net income and revenues.
For the period, ADAC reported revenues of $68.4 million, a 24%increase over the $55 million in sales reported for the firstquarter of 1996. Net income grew 44% to $5.1 million, comparedwith $3.5 million in the same period of 1996. ADAC also reportedrecord bookings of $82 million, adding $13 million to its backlog.
ADAC said the revenue growth was due to a 10% increase in servicerevenue and a 30% increase in product revenue. Product gross marginsgrew 3.7% to 41.8% in the period. ADAC also began volume shipmentsof its Molecular Coincidence Detection (MCD) high-energy imagingtechnique in the quarter.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.